Increased glucagon levels are commonly observed in T2D (5, 6) and have been independently associated with IR in non-T2D individuals (7), suggesting that SLE patients may show at least some level of pancreatic α-cell dysfunction, which could further increase the risk of T2D (8). The gene discussed is GCG; the disease is systemic lupus erythematosus.